Scholars@Duke publication: Tumor’s loss is clinician’s gain

Tumor’s loss is clinician’s gain

Journal articles

Ferrarelli, LK

Published in: Science Signaling

May 5, 2020

Published version (DOI) Publisher Link

A mutation in the epigenetic machinery creates a metabolic vulnerability in lung cancers.

Duke Scholars

Author Francis Ka-Ming Chan Integrative Immunobiology

Altmetric Attention Stats

Dimensions Citation Stats

Published In

Science Signaling

DOI

10.1126/scisignal.abc5604

EISSN

1937-9145

ISSN

1945-0877

Publication Date

May 5, 2020

Volume

Issue

630

Publisher

American Association for the Advancement of Science (AAAS)

Related Subject Headings

3101 Biochemistry and cell biology

Citation

APA

Chicago

ICMJE

MLA

NLM

Ferrarelli, L. K. (2020). Tumor’s loss is clinician’s gain. Science Signaling, 13(630). https://doi.org/10.1126/scisignal.abc5604

Ferrarelli, Leslie K. “Tumor’s loss is clinician’s gain.” Science Signaling 13, no. 630 (May 5, 2020). https://doi.org/10.1126/scisignal.abc5604.

Ferrarelli LK. Tumor’s loss is clinician’s gain. Science Signaling. 2020 May 5;13(630).

Ferrarelli, Leslie K. “Tumor’s loss is clinician’s gain.” Science Signaling, vol. 13, no. 630, American Association for the Advancement of Science (AAAS), May 2020. Crossref, doi:10.1126/scisignal.abc5604.

Ferrarelli LK. Tumor’s loss is clinician’s gain. Science Signaling. American Association for the Advancement of Science (AAAS); 2020 May 5;13(630).

Published In

Science Signaling

DOI

10.1126/scisignal.abc5604

EISSN

1937-9145

ISSN

1945-0877

Publication Date

May 5, 2020

Volume

Issue

630

Publisher

American Association for the Advancement of Science (AAAS)

Related Subject Headings

3101 Biochemistry and cell biology